Whether a cancer survivor had a health savings account (HSA) as part of their high-deductible health plan was linked to access to care.
Christina Bennett, MS
Study researchers polled 607 women who'd been previously diagnosed with breast cancer to see how recovery time, surgical complications, and cost factored into their decision to receive surgery during treatment.
A new study shows patients with advanced non–small-cell lung cancer have preferences on which chemotherapy side effects they'd prefer to avoid which highlights the importance of incorporating patient preferences into treatment.
A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.
A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
A total of 30 patients were enrolled in an expansion cohort for relapsed/refractory primary mediastinal B-cell lymphoma and received nivolumab and brentuximab vedotin.
While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.
Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer recurrence-free survival.
Researchers looked at the time between receiving a diagnosis and beginning chemotherapy to see if a delay in treatment impacted the overall survival in patients with breast cancer.